These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9204656)

  • 1. Octreotide may prevent definitive intestinal obstruction.
    Mercadante S; Kargar J; Nicolosi G
    J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
    Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
    Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
    Berger J; Lester P; Rodrigues L
    Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S; Porzio G
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C; Zulian GB
    Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment with octreotide for functional obstructions in scleroderma].
    Emmerich J; Roux ME; Capron L; Fiessinger JN
    Presse Med; 1992 Feb; 21(7):316-7. PubMed ID: 1532651
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
    Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
    J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of octreotide in malignant bowel obstruction.
    Krammer LM
    Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide in malignant intestinal obstruction.
    Pandha HS; Waxman J
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
    Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
    Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
    J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
    Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C; Galeazzi G
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisecretory agents in gastrointestinal obstruction.
    Muir JC; von Gunten CF
    Clin Geriatr Med; 2000 May; 16(2):327-34. PubMed ID: 10783431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.